Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.
Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.
复制标题
DOI：
10.1007/s10620-018-5000-0
复制
发表时间：
2018-05
影响因子：
3.1
通讯作者：
White J
中科院分区：
文献类型：
--
作者：
Mohapatra SS;Batra SK;Bharadwaj S;Bouvet M;Cosman B;Goel A;Jogunoori W;Kelley MJ;Mishra L;Mishra B;Mohapatra S;Patel B;Pisegna JR;Raufman JP;Rao S;Roy H;Scheuner M;Singh S;Vidyarthi G;White J
结直肠癌（CRC）占退伍军人所有癌症的约9%，这一事实引起了VA研究和开发工作的极大关注。召开了一次以实地为基础的结直肠癌专家会议，讨论结直肠癌精准医学的挑战和机遇。该小组被称为VA结直肠癌细胞基因组学联盟（VA4C），讨论了CRC生物学、生物标志物和早期检测和预防成像的进展。会议还讨论了精确治疗，包括荧光引导手术、靶向化疗和免疫疗法以及个性化癌症治疗方法。总体目标是确定可能最终导致个性化癌症诊断和治疗的模式。这篇综述总结了这次以VA为基础的会议的结果，其中讨论了目前关于CRC预筛查和治疗的许多知识。结论是，有必要也有机会确定预防结直肠癌的新靶点和开发晚期疾病的有效治疗方法。此外，开发将基因组检测与基于肿瘤的临床药物反应相结合的方法可能会导致更准确的CRC诊断和预后以及更有效的个性化治疗。
Colorectal cancer (CRC) accounts for ~9% of all cancers in the Veteran population, a fact which has focused a great deal of the attention of the VA’s research and development efforts. A field-based meeting of CRC experts was convened to discuss both challenges and opportunities in precision medicine for CRC. This group, designated as the VA Colorectal Cancer Cell-genomics Consortium (VA4C), discussed advances in CRC biology, biomarkers, and imaging for early detection and prevention. There was also a discussion of precision treatment involving fluorescence-guided surgery, targeted chemotherapies and immunotherapies, and personalized cancer treatment approaches. The overarching goal was to identify modalities that might ultimately lead to personalized cancer diagnosis and treatment. This review summarizes the findings of this VA field-based meeting, in which much of the current knowledge on CRC prescreening and treatment was discussed. It was concluded that there is a need and an opportunity to identify new targets for both the prevention of CRC and the development of effective therapies for advanced disease. Also, developing methods integrating genomic testing with tumoroid-based clinical drug response might lead to more accurate diagnosis and prognostication and more effective personalized treatment of CRC.
登录
查看更多内容
影响因子：
9.7
作者：
Fan, CW;Fan, HA;Chan, EC
通讯作者：
Chan, EC
影响因子：
9.3
作者：
Dik, Vincent K.;Gralnek, Ian M.;Siersema, Peter D.
通讯作者：
Siersema, Peter D.
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
3.6
作者：
通讯作者：
--
影响因子：
2.6
作者：
Dong L;Wang W;Li A;Kansal R;Chen Y;Chen H;Li X
通讯作者：
Li X